Status:
RECRUITING
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
Lead Sponsor:
Evommune, Inc.
Conditions:
Atoptic Dermatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Eligibility Criteria
Inclusion
- Chronic AD that has been present for ≥6 months
- Validated-Investigator's Global Assessment score of ≥3
- EASI of ≥16
- BSA of AD involvement of ≥10%
Exclusion
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
- Use of certain medications
- Presence of skin comorbidities or other condition(s) that may interfere with study assessments
- Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
Key Trial Info
Start Date :
August 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07150845
Start Date
August 26 2025
End Date
July 1 2026
Last Update
December 16 2025
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Dermatology Clinical Research
Fremont, California, United States, 94538
2
Metropolis Dermatology - Downtown Los Angeles
Los Angeles, California, United States, 90017
3
Skin and Beauty Center
Pasadena, California, United States, 91105
4
Skin Care Research, LLC
Boca Raton, Florida, United States, 33486